Skip to main content
. 2016 Dec 15;2016(12):CD006918. doi: 10.1002/14651858.CD006918.pub3

Vanover 2014.

Methods Allocation: randomised.
 Blindness: double blind.
Duration: 28 days.
 Design: parallel.
Participants Diagnosis: acute exacerbated schizophrenia (DSM‐IV).
 N = not reported.
 Age: not reported.
 Sex: not reported.
Length of illness: not reported.
 Inclusion criteria: not reported.
 Exclusion criteria: not reported.
Interventions 1. Risperidone: 4 mg/d.
 2. Placebo.
3. ITI‐007 60 mg/d.
4. ITI‐007 120 mg/d.
Outcomes Uable to use:
PANSS, CDSS.
Notes No full text available, we contacted the author (Kimberly Vanover, Ph.D. kvanover@intracellulartherapies.com) but havn't received a reply yet.